Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.

Stuart Grant Biography and Net Worth

Major Shareholder of Eyenovia

Stuart Grant is the Major Shareholder of Eyenovia.

What is Stuart M. Grant's net worth?: The estimated net worth of Stuart M. Grant is at least $5.65 million as of July 2nd, 2024. Grant owns 10,914,153 shares of Eyenovia stock worth more than $5,654,623 as of November 5th. This net worth approximation does not reflect any other investments that Grant may own. Learn More about Stuart M. Grant's net worth.
How do I contact Stuart M. Grant?: The corporate mailing address for Grant and other Eyenovia executives is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. Eyenovia can also be reached via phone at (917) 289-1117 and via email at [email protected]. Learn More on Stuart M. Grant's contact information.
Has Stuart M. Grant been buying or selling shares of Eyenovia?: Stuart M. Grant has not been actively trading shares of Eyenovia during the last quarter. Most recently, on Tuesday, July 2nd, Stuart M. Grant bought 1,515,151 shares of Eyenovia stock. The stock was acquired at an average cost of $0.66 per share, with a total value of $999,999.66. Following the completion of the transaction, the insider now directly owns 10,914,153 shares of the company's stock, valued at $7,203,340.98. Learn More on Stuart M. Grant's trading history.
Who are Eyenovia's active insiders?: Eyenovia's insider roster includes Stuart Grant (Major Shareholder), Tsontcho Ianchulev (CEO), Kenneth Lee, Jr. (Director), Charles Mather, IV (Director), and Michael Rowe (COO). Learn More on Eyenovia's active insiders.
Are insiders buying or selling shares of Eyenovia?: In the last twelve months, Eyenovia insiders bought shares 7 times. They purchased a total of 1,757,829 shares worth more than $1,225,659.84. The most recent insider tranaction occured on August, 28th when CEO Michael M Rowe bought 27,071 shares worth more than $14,076.92. Insiders at Eyenovia own 7.1% of the company. Learn More about insider trades at Eyenovia.
Information on this page was last updated on 8/28/2024.

Stuart M. Grant Insider Trading History at Eyenovia

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/2/2024	Buy	1,515,151	$0.66	$999,999.66	10,914,153
3/28/2024	Buy	100,000	$0.98	$98,000.00	5,430,715
3/19/2024	Buy	50,000	$1.23	$61,500.00	5,330,715
3/8/2024	Buy	10,717	$1.58	$16,932.86	5,280,715
8/16/2023	Buy	45,000	$1.91	$85,950.00	5,239,998
5/25/2023	Buy	88,247	$2.65	$233,854.55	5,194,998
6/21/2022	Buy	100,000	$1.65	$165,000.00	5,084,998
5/10/2022	Buy	50,000	$1.98	$99,000.00	4,959,998
5/4/2022	Buy	24,074	$2.26	$54,407.24	4,909,998
4/21/2022	Buy	38,800	$2.59	$100,492.00	4,865,924
2/22/2022	Buy	42,000	$2.75	$115,500.00
2/18/2022	Buy	10,000	$2.85	$28,500.00
2/7/2022	Buy	36,030	$2.97	$107,009.10
12/15/2021	Buy	100,000	$3.45	$345,000.00
11/15/2021	Buy	75,000	$3.64	$273,000.00
10/29/2021	Buy	15,505	$3.75	$58,143.75
10/25/2021	Buy	33,806	$4.00	$135,224.00
8/19/2021	Buy	50,000	$3.98	$199,000.00
8/17/2021	Buy	23,419	$4.00	$93,676.00
4/19/2021	Buy	30,692	$4.89	$150,083.88	4,279,748
3/5/2021	Buy	35,000	$5.50	$192,500.00	4,254,748
10/12/2020	Buy	100,000	$3.55	$355,000.00	4,169,748
9/24/2020	Buy	75,000	$2.99	$224,250.00	4,069,748
8/19/2020	Buy	333,000	$3.60	$1,198,800.00	3,593,128
3/23/2020	Buy	903,240	$2.06	$1,860,674.40
11/12/2019	Buy	29,945	$2.70	$80,851.50	2,226,183
10/30/2019	Buy	25,000	$2.85	$71,250.00	2,226,183
10/16/2019	Buy	15,000	$3.14	$47,100.00	2,226,183
10/14/2019	Buy	6,700	$3.25	$21,775.00	2,226,183
10/2/2019	Buy	5,000	$3.33	$16,650.00	2,226,183
9/30/2019	Buy	17,940	$3.70	$66,378.00	2,226,183
9/27/2019	Buy	312	$4.00	$1,248.00	2,226,183

Stuart M. Grant Buying and Selling Activity at Eyenovia

Eyenovia Company Overview

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

Today's Range

Now: $0.52

$0.50

$0.54

50 Day Range

MA: $0.51

$0.44

$0.59

2 Week Range

Now: $0.52

$0.37

$2.57

Volume

424,107 shs

Average Volume

1,203,719 shs

Market Capitalization

$33.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.75

625,000% Gain

From Crypto Swap Profits | Ad

>> Dive into the Workshop Here